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Special issue on sphingolipidsIt is now over 120 years since sphingolipids were first
described in biological systems. Typically and for many years,
these lipids were considered to be essential building blocks of
the plasma membranes of all eukaryotic cells and of some
prokaryotic organisms or viruses. Nowadays, numerous
sphingolipids are known to be highly bioactive, and many of
them are implicated in the regulation of diverse cellular
functions.
The regulation of metabolism by sphingolipids became the
focus of attention for many researchers after the discovery by
Hannun and et al. [1] and Merrill et al. [2] of the inhibition of
protein kinase C (PKC) by sphingoid bases in 1986. Soon
afterward, Kolesnick [3] demonstrated the stimulation of an
acid sphingomyelinase that was sensitive to exogenous addition
of a cell-permeable analog of diacylglycerol in pituitary cells.
This action caused sphingomyelin hydrolysis and a concomitant
increase in ceramide levels that were independent of protein
kinase C. It was suggested that sphingolipid-derived metabo-
lites could function as second messengers. This hypothesis was
confirmed later by the elucidation of the sphingomyelin
pathway, the physiological functions of ceramide [4,5], and
the regulation of cell proliferation and apoptosis through
sphingosine 1-phosphate by Spiegel's group [6,7]. As for
many bioactive lipids in general, some mechanistic aspects of
sphingolipid actions may implicate the translocation of specific
proteins that are able to interact with these sphingolipids
through specific domains. Therefore, sphingolipid signaling
mechanisms may often involve specific lipid–protein interac-
tions at defined subcellular locations.
Also, a crucial aspect of the actions or metabolism of
sphingolipid is their participation in pathological processes
[8]. Many sphingolipids, or the enzymes involved in their
metabolism, are instrumental in the development of0005-2736/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2006.09.017pathological processes ranging from the well-known Nie-
mann–Pick disease to the development of drug resistances,
together with Gaucher and neurodegenerative diseases,
cardiovascular diseases, insulin resistance, or various forms
of cancer.
The topics selected for this special issue are all at the cutting
edge of sphingolipid signaling research, in which rapid
advances have been made in recent years. We are confident
that this collection of carefully selected papers will provide the
reader with an up-to-date view on the sphingolipid properties
and metabolism, its regulation, and the molecular aspects of
sphingolipid-based disease.
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